Journal Information
Vol. 88. Issue 4.
Pages 454 (October - December 2023)
Share
Share
Download PDF
More article options
Vol. 88. Issue 4.
Pages 454 (October - December 2023)
Letter to the Editor
Full text access
Answer to Sánchez-Luque et al. regarding “The Roussel-Uclaf hepatotoxicity causality assessment method in the context of diagnostic suspicion of drug-induced liver damage: Is it still valid?”
Respuesta a Sánchez-Luque et al.: «El método de evaluación de causalidad de hepatotoxicidad de Roussel-Uclaf (RUCAM) en el contexto de sospecha diagnóstica de daño hepático inducido por medicamentos DILI: ¿es aún vigente?»
Visits
1446
O.M. Ardila-Suáreza,
Corresponding author
oscarardila@clinicaces.edu.co

Corresponding author. Extensión 7248; Departamento de Gastroenterología y Hepatología, Clínica CES, Medellín, Colombia. Tel.: +57 4 5767272.
, L. Oriz-Benjumeab, A.A. Artetac,d, L.G. Guevara-Casallasa
a Departamento de Gastroenterología y Hepatología, Clínica CES, Medellín, Colombia
b Unidad de Cuidados Intensivos, Clínica CES, Medellín, Colombia
c Departamento de Patología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
d Grupo de Investigaciones en Patología, Universidad de Antioquia (GRIP-UdeA), Medellín, Colombia
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text

We have attentively read the letter to the editor by Dr. Sánchez Luque, with respect to the absence of the Roussel-Uclaf hepatotoxicity causality assessment method (RUCAM) in our study. Unfortunately, all the variables required for completing the latest version of that scoring method were not available in all the cases we studied.1 We compiled our study population from a database of histopathologic reports of liver samples, not from the viewpoint of the treating clinicians. Thus, added to the limitations inherent in retrospective studies, data, such as the course of ALT levels at 180 days of follow-up and all the tests for determining alternate causes, were not available for the majority of cases. Likewise, the specific question about previous reactions to a given drug or substance, involving liver damage, or re-exposures to those agents, were not reported in the clinical histories of each patient.

Therefore, had we calculated the score of the RUCAM in our cases, the result would inevitably have been erroneous and most likely lower than the hypothetically real one, in turn, leading to disinformation about the accuracy of the tool for analyzing such cases. As Dr. Sánchez Luque correctly pointed out, the accuracy of the RUCAM is very high, but requires a level of quality and checklist that are not always available in retrospective studies.

Financial disclosure

No financial support was received in relation to this letter.

Conflict of interest

The authors declare that there is no conflict of interest.

Reference
[1]
A.B. Sánchez-Luque.
El método de evaluación de causalidad de hepatotoxicidad de Roussel-Uclaf (RUCAM) en el contexto de sospecha diagnóstica de daño hepático inducido por medicamentos DILI: es aún vigente?.
Rev Gastroenterol Mex, 88 (2023),

Please cite this article as: Ardila-Suárez OM, Oriz-Benjumea L, Arteta AA, Guevara-Casallas LG. Respuesta a Sánchez-Luque et al.: «El método de evaluación de causalidad de hepatotoxicidad de Roussel-Uclaf (RUCAM) en el contexto de sospecha diagnóstica de daño hepático inducido por medicamentos DILI: ¿es aún vigente?» Rev Gastroenterol Mex. 2023;88:454.

Copyright © 2023. Asociación Mexicana de Gastroenterología
Idiomas
Revista de Gastroenterología de México
Article options
Tools
es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.